Cabozantinib as a novel therapy for renal cell carcinoma (Q39490838)

12 September 2017

Cabozantinib as a novel therapy for renal cell carcinoma (English)

1 reference

12 September 2017

1 reference

ChEBI release 2020-05-28

Ulka Vaishampayan

1

1 reference

12 September 2017

1 April 2013

1 reference

12 September 2017

Current Oncology Reports

1 reference

12 September 2017

15

1 reference

12 September 2017

2

1 reference

12 September 2017

76-82

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-012-0289-x

12 September 2017

0 references

cites work

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Hepatocyte growth factor, its receptor, and their potential value in cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

MET and VEGF: synergistic targets in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

High expression of the Met receptor in prostate cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB/c-MC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-012-0289-X

Commentary on "Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial." Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaisham

21 January 2018

1 reference

12 December 2020

Therapeutic targeting of the receptor tyrosine kinase Met.

1 reference

12 December 2020

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

1 reference

12 December 2020

Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

1 reference

12 December 2020

10.1007/S11912-012-0289-X

Identifiers

DOI

1 reference

12 September 2017

1 reference

PubMed ID

23292795